One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors

NCT06781125 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumors

Interventions

DRUG: JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion

Sponsor

Immorna Biotherapeutics, Inc.